The anticoagulant effect of hexolame, N-(3-hydroxy-1,3,5(10)-estratrien-17ß-yl)-6-hydroxyhexylamine, another amino-estrogen with prolonged anticoagulant effect
Por:
Rubio-Póo C., Lemini C., García-Mondragón J., de la Peña A., Jayme V., Mendoz-Patiño N., Zavala E., Silva G., Blickenstaff R.T., Fernández-G. J.M., Mandoki J.J.
Publicada:
1 ene 1990
Resumen:
The anticoagulant and estrogenic effects of hexolame, N-(3-hydroxy-1,3,5(10)-estratrien-17?-yl)-6-hydroxyhexylamine, are described. A single subcutaneous injection of hexolame in adult and infant male mice produced dose-dependent increases in blood clotting time which could be observed even after 2 days. In ovariectomized mice, hexolame produced vaginal cornification (estrogenic response). The data suggested that if used in the treatment of prostatic cancer, hexolame, like prolame, would not induce cardiovascular accidents. It could also be useful in the prevention of thrombosis. (Steroids 55:83-86, 1990). © 1990.
Filiaciones:
Sección de Farmacología, ENEP-Zaragoza, Indiana University School of Medicine, Indianapolis, IN, United States
Departamento de Farmacología, Facultad de Medicina, Indiana University School of Medicine, Indianapolis, IN, United States
Veterans Administration Medical Center, Department of Biochemistry, Indiana University School of Medicine, Indianapolis, IN, United States
Institute de Química, Universidad Nacionale Autónoma de México, Ciudad Universitaria, México, Indiana University School of Medicine, Indianapolis, Indiana, USA
|